Abstract: 【Abstract】 The interleukin-36 pathway plays an important role in the pathogenesis of various inflammatory skin diseases, including generalized pustular psoriasis （GPP）. Anti-interleukin-36R monoclonal antibodies, represented by spesolimab, provide more therapeutic options for GPP and other inflammatory skin diseases. The Chinese Society of Dermatology, the China Dermatologist Association, and other institutions convened experts in the relevant field to develop this consensus to provide recommendations on the indications, treatment regimens, and safety management of spesolimab in inflammatory skin diseases, such as GPP, localized pustular psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, acute febrile neutrophilic dermatosis, and acute generalized exanthematous pustulosis, with the aim of guiding its clinical application. The application of spesolimab in special populations such as pediatric, pregnant, and elderly patients requires further clinical evidence. Future studies should focus on the long-term efficacy and safety of spesolimab in the treatment of GPP, and explore its potential in treating inflammatory skin diseases, particularly refractory neutrophilic dermatoses.

Key words: anti-IL-36R monoclonal antibodies, spesolimab, inflammatory skin diseases, generalized pustular psoriasis, expert consensus